Arthneeti
Sale is live|00:00:00
Insecticides India LtdQ2 FY24

Insecticides India Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: 669P/E: 14.8Market Cap: ₹2.1K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Volume growth for FY25 is expected to be 15% to 20%.
  • Value (revenue) growth anticipated to be near 10% for FY25.
  • Premium products (Focus Maharatna and Maharatna) targeted for strong double-digit growth.
  • Contribution from premium products in Q1 was about 60% of total B2C sales.
  • New products (launched in last 4 years) contribute around 33% of B2C net sales.
  • Continuous launch of 6-7 premium products annually, mostly patent-protected mixtures.
  • Expected growth in premium segment revenue from ₹800 crore (last fiscal) to ₹1,000 crore (current fiscal).
  • Long-term margin improvement goal to reach 75% contribution from premium products in 3-4 years.
  • Dahej plant expected to add ₹250–₹300 crore revenue potential next year.
  • Seasonality: Q1 and Q2 are strongest quarters; Q3 and Q4 have lower sales volumes.

Margin guidance

Category 1
  • The company expects a healthy volume growth of 15% to 20% in the current fiscal year.
  • Revenue growth is anticipated to be in the double-digit range, though not much higher than that (around 10%).
  • EBITDA margin improvement is expected, with a current increase of about 300 basis points and a forecasted growth of approximately 100 basis points per annum going forward.
  • EBITDA margin for the full year is expected to remain in double digits, possibly close to or surpassing 11%, contingent on favorable monsoon and crop conditions.
  • Profitability growth is projected to improve from a previous negative 7% to a positive 10% this year.
  • The company is focused on growing its premium products (Focus Maharatna and Maharatna) which currently contribute significantly to margins and profitability.
  • Continued product premiumization and internal production efficiencies, such as backward integration, are expected to drive margin expansion and earnings growth.

3 more insights locked — sign up free to unlock

Fundraise plans

  • There is no explicit mention of any current or planned fundraising through debt or equity in the provided transcript.
  • The Company is investing in expansion projects such as the Sotanala project (CAPEX ~100 crores) and a new plant in Dahej (~150 crores CAPEX) funded internally.
  • The Dahej plant commissioning is pending government approvals; production is expected to start soon.
  • The focus appears to be on internal cash flows and operational efficiencies rather than external fundraising.
  • No specific details were shared about issuing new equity or taking on new debt during the call.

Order book

  • The document does not explicitly mention the current or expected order book or pending orders for Insecticides (India) Limited.
  • However, it reflects a positive outlook on demand due to good rainfall and extended sowing seasons leading to higher market opportunities.
  • The company expects strong sales growth, especially in premium products (Focus Maharatna and Maharatna).
  • Volume growth of 15%-20% and value growth near 10% are anticipated for the fiscal year.
  • The business is witnessing good demand in B2C segments, while B2B faces challenges but expects recovery with margin improvements.
  • New product launches and capacity expansions (Sotanala and Dahej plants) are expected to support future order fulfillment and growth.
  • Overall, the company remains optimistic about the crop protection industry's outlook and sales momentum for the coming quarters.

Capex plans

Yes
  • The company has a CAPEX plan of around ₹100 crore for the Sotanala project in Behror, Rajasthan, where it will build formulation and technical facilities for insecticides and fungicides. This project is expected to be completed in 1 to 1.5 years.
  • Expansion of the formulation facility in Dahej is planned to support volume growth, for which permissions are already obtained.
  • A new plant in Dahej called the L&T plant has been constructed with an investment of over ₹105 crore, doubling technical synthesis capacity. Production is pending state government approval but expected soon, with the plant likely starting operations within a month.
  • This Dahej plant will enable backward integration for certain intermediates, helping reduce costs and stabilize manufacturing.
  • The Dahej plant has a revenue potential of ₹250-300 crore starting next fiscal but may partly serve internal consumption.
  • Continuous investments are being made in technology, R&D, and premium product launches.

How does Insecticides India Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature
1Insecticides India Ltd
Rev 3Mar 1

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like Insecticides India Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio